ANI Pharmaceuticals (ANIP) stock soared 5.00% in Wednesday's intraday trading session, boosted by a positive analyst report.
In a research note released on January 13th, analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on ANI Pharmaceuticals. The firm's bullish outlook on the pharmaceutical company likely reinforced investor confidence, driving up the stock's price.
ANI Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures, and markets affordable medications primarily in the areas of oncology, anti-nausea, and hypertension. The company has a diversified product portfolio and a strong pipeline of potential drug candidates.